Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.38
-0.03 (-0.17%)
Streaming Delayed Price
Updated: 9:32 AM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
October 10, 2024
Via
Benzinga
Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
October 08, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
October 03, 2024
Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.
Via
Benzinga
Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
October 03, 2024
From
Teva Pharmaceutical Industries Ltd; mAbxience
Via
GlobeNewswire
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today
September 16, 2024
Via
Benzinga
Key Takeaways From Teva Pharmaceutical Indus Analyst Ratings
September 03, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today
August 21, 2024
Via
Benzinga
Teva Launches Generic Version Of Sandostatin In The US
October 01, 2024
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know.
Via
Benzinga
Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
October 01, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
September 30, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
$1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
September 30, 2024
Via
Benzinga
Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
September 30, 2024
Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...
Via
Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
September 24, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
September 23, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
September 21, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Teva to Present at the Bank of America 2024 Global Healthcare Conference
September 11, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
UnitedHealth Follows Competitors, Replaces Humira with Lower-Cost Biosimilars
September 11, 2024
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amgen's Amjevita, in a move aimed at cutting prescription costs.
Via
Benzinga
Teva Announces $80M Settlement To Baltimore: City Continues Opioid Litigation Against Other Companies
September 10, 2024
Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated to education, recovery centers, and outreach initiatives.
Via
Benzinga
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
September 06, 2024
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.
Via
Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
September 06, 2024
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.
Via
Benzinga
Organon Stock Sees Relative Strength Rating Rise To 91
August 27, 2024
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Via
Investor's Business Daily
Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 26, 2024
From
Teva Pharmaceutical Industries Ltd
Via
GlobeNewswire
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
August 23, 2024
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...
Via
Benzinga
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
August 20, 2024
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Via
Investor's Business Daily
$100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
August 13, 2024
Via
Benzinga
The 7 Best Under $20 Stocks to Buy in August 2024
August 07, 2024
Although cheap stocks are often cheap for a reason, it doesn't hold true for the best stocks under $20, which is where investors can profit.
Via
InvestorPlace
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment
August 06, 2024
New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...
Via
PressReach
Exposures
Product Safety
What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.
August 02, 2024
Figuring out the hottest biotech stocks can be as simple as looking at the most traded stocks by volume in the last 24 hours.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.